Please provide your email address to receive an email when new articles are posted on . Three of four patients who received an investigational chimeric antigen receptor T-cell therapy for diffuse ...

EMulate Therapeutics, Inc. (EMTx) announces the acceptance of a publication of its pre-clinical animal model, testing the effect of its ulRFE® paclitaxel (A1A) signal against a DIPG tumor cell line.

Please provide your email address to receive an email when new articles are posted on . Researchers recently presented early data on the efficacy of chimeric antigen receptor T-cell therapy for ...

Credit: Jazz Pharmaceuticals. Modeyso is the first FDA-approved treatment for this rare brain tumor. Continued approval for this indication is contingent upon verification of clinical benefit in the ...

Vorasidenib is an investigational oral, selective, highly brain-penetrant dual inhibitor of IDH1/2 enzymes. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...

Children diagnosed with diffuse midline gliomas often die within a year after their initial diagnosis since there are no effective treatments yet for this rare cancer. But researchers now have a ...

Diffuse intrinsic pontine glioma (DIPG) is an almost universally fatal brain pediatric tumor and the only tumor indication where palliative radiotherapy is the current standard of care. Although ...